Diabetic Retinopathy - Pipeline Review, H2 2017

Date: November 14, 2017
Pages: 195
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: DEF78385DBEEN
Leaflet:

Download PDF Leaflet

Diabetic Retinopathy - Pipeline Review, H2 2017
Diabetic Retinopathy - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Retinopathy - Pipeline Review, H2 2017, provides an overview of the Diabetic Retinopathy (Metabolic Disorders) pipeline landscape.

Diabetic retinopathy is a complication of diabetes that affects the eyes. Diabetic retinopathy symptoms may include spots or dark strings floating in vision (floaters), blurred vision, fluctuating vision, vision loss and difficulty with color perception. The predisposing factors include diabetes, high blood pressure, high cholesterol, pregnancy and tobacco use.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Retinopathy - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Diabetic Retinopathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Retinopathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Retinopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 8, 6, 1, 38, 10 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 6 molecules, respectively.

Diabetic Retinopathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Retinopathy (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Diabetic Retinopathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Diabetic Retinopathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Diabetic Retinopathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Retinopathy (Metabolic Disorders)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Diabetic Retinopathy (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Diabetic Retinopathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Diabetic Retinopathy - Overview
Diabetic Retinopathy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Diabetic Retinopathy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Diabetic Retinopathy - Companies Involved in Therapeutics Development
Abzena Plc
Acucela Inc
Aerie Pharmaceuticals Inc
Aerpio Therapeutics Inc
Antisense Therapeutics Ltd
AntriaBio Inc
BCN Peptides SA
Boehringer Ingelheim GmbH
Charlesson LLC
Coherus BioSciences Inc
Crinetics Pharmaceuticals Inc
Dimerix Bioscience Pty Ltd
Dynamis Therapeutics Inc
EyeGene Inc
F. Hoffmann-La Roche Ltd
Foresee Pharmaceuticals LLC
Icon Bioscience Inc
Islet Sciences Inc
Kodiak Sciences Inc
Kowa Co Ltd
Lupin Ltd
M's Science Corp
Mabion SA
Navigen Inc
Nemus Bioscience Inc
Oculis ehf
Ohr Pharmaceutical Inc
PanOptica Inc
Profarma
Promedior Inc
Regeneron Pharmaceuticals Inc
Ribomic Inc
Strongbridge Biopharma plc
Sylentis SAU
ThromboGenics NV
VESSL Therapeutics Ltd
Diabetic Retinopathy - Drug Profiles
(irbesartan + propagermanium) - Drug Profile
A-717 - Drug Profile
AB-402 - Drug Profile
AC-301 - Drug Profile
aflibercept - Drug Profile
aflibercept biosimilar - Drug Profile
AKB-9778 - Drug Profile
Antisense RNAi Oligonucleotide to Inhibit ProRenin Receptor for Uveitis and Diabetic Retinopathy - Drug Profile
APTA-1004 - Drug Profile
Aptamers for Diabetic Retinopathy - Drug Profile
AQA-001 - Drug Profile
AR-13154 - Drug Profile
atesidorsen sodium - Drug Profile
BI-1467335 - Drug Profile
BI-690517 - Drug Profile
Biologics to Inhibit Semaphorin 3A and VEGF for Diabetic Complications - Drug Profile
BNN-27 - Drug Profile
Cell Therapy for Diabetic Retinopathy - Drug Profile
CLT-005 - Drug Profile
CLT-020 - Drug Profile
CRN-00808 - Drug Profile
cyclosporine - Drug Profile
Cyndacel-M - Drug Profile
DRGT-109 - Drug Profile
DT-23552 - Drug Profile
DYN-12 - Drug Profile
E-1086 - Drug Profile
EG-Mirotin - Drug Profile
emixustat hydrochloride - Drug Profile
fenofibrate - Drug Profile
FP-008 - Drug Profile
Gene Therapy for Diabetic Retinopathy - Drug Profile
GLY-230 - Drug Profile
HCB-1019 - Drug Profile
IVMED-60 - Drug Profile
JP-153 - Drug Profile
KSI-301 - Drug Profile
magacizumab - Drug Profile
Monoclonal Antibody to Inhibit IAP for Diabetic Retinopathy - Drug Profile
MS-553 - Drug Profile
NB-2222 - Drug Profile
NM-108 - Drug Profile
OC-410 - Drug Profile
ocriplasmin - Drug Profile
OCU-200 - Drug Profile
OCX-063 - Drug Profile
PAN-90806 - Drug Profile
Peptagon - Drug Profile
PF-07 - Drug Profile
PRM-167 - Drug Profile
Protein for Oncology, Ophthalmology and Metabolic Disorders - Drug Profile
ranibizumab biosimilar - Drug Profile
ranibizumab biosimilar - Drug Profile
ranibizumab biosimilar - Drug Profile
RBM-008 - Drug Profile
Recombinant Protein for Oncology, Diabetic Retinopathy and Retinopathy Of Prematurity - Drug Profile
Recombinant Protein to Activate Caspases for Diabetic Retinopathy, Age Related Macular Degeneration and Solid Tumor - Drug Profile
Recombinant Proteins to Inhibit VEGFA for Diabetic Retinopathy - Drug Profile
Resolvine ER - Drug Profile
ripasudil - Drug Profile
RO-5461111 - Drug Profile
RT-001 - Drug Profile
RT-002 - Drug Profile
SBT-200 - Drug Profile
Small Molecules to Inhibit ARF6 for Macular Degeneration and Diabetic Retinopathy - Drug Profile
somatostatin - Drug Profile
squalamine lactate - Drug Profile
Stem Cell Therapy for Diabetic Retinopathy - Drug Profile
Stem Cell Therapy for Interstitial Cystitis and Metabolic Disorders - Drug Profile
SYL-136001v10 - Drug Profile
THR-687 - Drug Profile
Vaxier-001 - Drug Profile
veldoreotide - Drug Profile
Wnt-001 - Drug Profile
Diabetic Retinopathy - Dormant Projects
Diabetic Retinopathy - Discontinued Products
Diabetic Retinopathy - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Diabetic Retinopathy, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Diabetic Retinopathy - Pipeline by Abzena Plc, H2 2017
Diabetic Retinopathy - Pipeline by Acucela Inc, H2 2017
Diabetic Retinopathy - Pipeline by Aerie Pharmaceuticals Inc, H2 2017
Diabetic Retinopathy - Pipeline by Aerpio Therapeutics Inc, H2 2017
Diabetic Retinopathy - Pipeline by Antisense Therapeutics Ltd, H2 2017
Diabetic Retinopathy - Pipeline by AntriaBio Inc, H2 2017
Diabetic Retinopathy - Pipeline by BCN Peptides SA, H2 2017
Diabetic Retinopathy - Pipeline by Boehringer Ingelheim GmbH, H2 2017
Diabetic Retinopathy - Pipeline by Charlesson LLC, H2 2017
Diabetic Retinopathy - Pipeline by Coherus BioSciences Inc, H2 2017
Diabetic Retinopathy - Pipeline by Crinetics Pharmaceuticals Inc, H2 2017
Diabetic Retinopathy - Pipeline by Dimerix Bioscience Pty Ltd, H2 2017
Diabetic Retinopathy - Pipeline by Dynamis Therapeutics Inc, H2 2017
Diabetic Retinopathy - Pipeline by EyeGene Inc, H2 2017
Diabetic Retinopathy - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
Diabetic Retinopathy - Pipeline by Foresee Pharmaceuticals LLC, H2 2017
Diabetic Retinopathy - Pipeline by Icon Bioscience Inc, H2 2017
Diabetic Retinopathy - Pipeline by Islet Sciences Inc, H2 2017
Diabetic Retinopathy - Pipeline by Kodiak Sciences Inc, H2 2017
Diabetic Retinopathy - Pipeline by Kowa Co Ltd, H2 2017
Diabetic Retinopathy - Pipeline by Lupin Ltd, H2 2017
Diabetic Retinopathy - Pipeline by M's Science Corp, H2 2017
Diabetic Retinopathy - Pipeline by Mabion SA, H2 2017
Diabetic Retinopathy - Pipeline by Navigen Inc, H2 2017
Diabetic Retinopathy - Pipeline by Nemus Bioscience Inc, H2 2017
Diabetic Retinopathy - Pipeline by Oculis ehf, H2 2017
Diabetic Retinopathy - Pipeline by Ohr Pharmaceutical Inc, H2 2017
Diabetic Retinopathy - Pipeline by PanOptica Inc, H2 2017
Diabetic Retinopathy - Pipeline by Profarma, H2 2017
Diabetic Retinopathy - Pipeline by Promedior Inc, H2 2017
Diabetic Retinopathy - Pipeline by Regeneron Pharmaceuticals Inc, H2 2017
Diabetic Retinopathy - Pipeline by Ribomic Inc, H2 2017
Diabetic Retinopathy - Pipeline by Strongbridge Biopharma plc, H2 2017
Diabetic Retinopathy - Pipeline by Sylentis SAU, H2 2017
Diabetic Retinopathy - Pipeline by ThromboGenics NV, H2 2017
Diabetic Retinopathy - Pipeline by VESSL Therapeutics Ltd, H2 2017
Diabetic Retinopathy - Dormant Projects, H2 2017
Diabetic Retinopathy - Dormant Projects, H2 2017 (Contd..1), H2 2017
Diabetic Retinopathy - Dormant Projects, H2 2017 (Contd..2), H2 2017
Diabetic Retinopathy - Dormant Projects, H2 2017 (Contd..3), H2 2017
Diabetic Retinopathy - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Diabetic Retinopathy, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

COMPANIES MENTIONED

Abzena Plc
Acucela Inc
Aerie Pharmaceuticals Inc
Aerpio Therapeutics Inc
Antisense Therapeutics Ltd
AntriaBio Inc
BCN Peptides SA
Boehringer Ingelheim GmbH
Charlesson LLC
Coherus BioSciences Inc
Crinetics Pharmaceuticals Inc
Dimerix Bioscience Pty Ltd
Dynamis Therapeutics Inc
EyeGene Inc
F. Hoffmann-La Roche Ltd
Foresee Pharmaceuticals LLC
Icon Bioscience Inc
Islet Sciences Inc
Kodiak Sciences Inc
Kowa Co Ltd
Lupin Ltd
M's Science Corp
Mabion SA
Navigen Inc
Nemus Bioscience Inc
Oculis ehf
Ohr Pharmaceutical Inc
PanOptica Inc
Profarma
Promedior Inc
Regeneron Pharmaceuticals Inc
Ribomic Inc
Strongbridge Biopharma plc
Sylentis SAU
ThromboGenics NV
VESSL Therapeutics Ltd
Skip to top


Ask Your Question

Diabetic Retinopathy - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: